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Abstract
Matrix metalloproteinase 7 (MMP7), a metallohydrolase involved in the development of several cancers, is downregulated in
the Apc
Min/+ colon cancer mouse model following sulindac treatment. To determine whether this effect is relevant to the
human condition, HT-29 human colon cancer cells were treated with sulindac and its metabolites, and compared to results
obtained from in vivo mouse studies. The expression of MMP7 was monitored. The results demonstrated that sulindac
sulfide effectively downregulated both MMP7 expression and activity. Furthermore, activity-based proteomics
demonstrated that sulindac sulfide dramatically decreased the activity of leukotriene A4 hydrolase in HT-29 cells as
reflected by a decrease in the level of its product, leukotriene B4. This study demonstrates that the effect of sulindac
treatment in a mouse model of colon cancer may be relevant to the human counterpart and highlights the effect of
sulindac treatment on metallohydrolases.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs), such as
sulindac, are chemo-preventive reagents towards colorectal
cancers [1,2,3]. This effect is consistent with observations in vitro
in human colon cancer cells [4], as well as in vivo in the Apc
Min/+
mouse model, where a large decrease in tumor burden is observed
[5]. The gastrointestinal complications that develop in NSAID
users are well documented [6], and represent an obstacle in the use
of these drugs as chemo-preventive agents. The pleiotropic effects
of sulindac on colon cancer prevention are still unclear and hinder
the development of more specific treatments with diminished side
effects. Regarding this issue, it has been shown that sulindac
treatment causes changes in extracellular matrix remodeling
events, including downregulation of matrix metalloproteinase 7
(MMP7) in intestinal adenomas of Apc
Min/+ mice [7].
MMP7 belongs to a group of metal ion-dependent proteases.
According to the MEROPS database (www.merops.sanger.uk),
matrix metalloproteases (MMPs), consisting of 24 members,
comprise the M10 subfamily of the MA family of the
metallohydrolases clan M. MMPs have been strongly implicated
in the development of many cancers. Deletion of MMP2 and
MMP9 in mice have been shown to reduce pancreatic tumori-
genesis by reducing angiogenesis [8]. Pertinent to this study,
MMP7 deletion in Apc
Min/+ mice has been shown to strongly
reduce intestinal tumor burden [9]. These observations implicate
MMP7 as a viable target for the development of novel treatment
regimes.
The current study determined the effect of sulindac treatment
on MMP7 in the human colon cancer cell line, HT-29, and
utilized a global approach to detect altered activities of other
metallohydrolases. The results of these investigations are described
herein.
Materials and Methods
Cell culture
HT-29 cells (American Type Culture Collection, Manassas,
VA) were maintained in McCoy’s 5A medium (Gibco, Grand
Island, NY) with 10% fetal bovine serum at 37uCi na n
atmosphere of 95% air/5% CO2. Sulindac, sulindac sulfide, and
sulindac sulfone were purchased from Sigma Aldrich (St. Louis,
MO). These drugs were diluted in dimethyl sulfoxide (DMSO).
DMSO was added to the media at a final concentration of 1% and
cells were cultured in 6-well plates. Once cells were 80% confluent,
they were treated with various concentrations of sulindac and its
metabolites. After 24 hr, the cells were trypsinized and viable cells
counted using the trypan blue method.
Gene expression
HT-29 cells, at the time of harvest, were trypsinized,
centrifuged, and the cell pellet used to extract RNA following
the Qiagen protocol. Concentration and quality of the samples
were assessed using the spectral profile obtained from the
NanoDrop-1000 (Thermo Scientific, Wilmington, DE). Real-time
reverse transcription–polymerase chain reaction (RT-PCR) was
performed as previously described [7]. Primers and probes
designed for human MMP7, MMP25, Trypsin1, and RPL-19 are
shown in Table 1.
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cells, treated with DMSO or 100 mM sulindac sulfide for 24 hr
using the Qiagen protocol. RT-PCR reaction included 2.56
Hotmaster Mix (5 Primer Inc., Gaithersburg, MD), RNase
Inhibitor, Multiscribe RT enzyme, passive reference dye ROX,
and Sybr Green. Total RNA (25 ng) was revere-transcribed in
30 ml reaction mixture at 48uC for 30 min. The following
conditions were used for amplification: pre-denaturation for
5 min at 95uC, 30 cycles of denaturation at 95uC for 20 sec,
annealing at 59uC for 20 sec, and extension at 72uC for 25 sec.
PCR products were separated by electrophoresis on a 3% agarose
gel containing ethidium bromide. A 50 bp DNA ladder
(Promega, Madison, WI) was used as the molecular weight
marker.
Western blotting
Proteomes were extracted from HT-29 cells and then treated
with sulindac sulfide (100 mM) for 24 hr at 80% confluency.
Cells were trypsinized, centrifuged, and then washed in PBS.
Cell pellets were then Dounce homogenized and sonicated. The
proteome was centrifuged at 100,0006 g to separate the
cytosolic and membrane fractions. The secreted fraction was
obtained by centrifugation of the cell media at 100,0006g.T h e
proteome was precipitated by the addition of ammonium
sulfate. Samples were passed over a PD-10 desalting column
(GE Healthcare, Piscataway, NJ) and protein concentrations
were determined using the NanoDrop-1000 (Thermo Scientific,
Wilmington, DE). Samples were load onto a 10% polyacryl-
amide gel, electrophoresed, and then transferred to a PVDF
membrane. The membranes were incubated overnight at 4uC
with polyclonal rabbit-anti-human MMP7 (Abcam, Cambridge
MA), and polyclonal rabbit-antihuman active MMP7 (Abcam)
at 1 mg/ml in blocking buffer (PBS, 3% nonfat dry milk, 0.1%
Tween 20). For MMP25 and a-Tubulin, rabbit anti-human
MMP25 (Abcam) and mouse anti-human a-Tubulin (Santa
Cruz Technology), respectively, was used. HRP-conjugated
anti-rabbit IgG antibody or HRP-conjugated-anti-mouse IgG
(Cell Signaling Technology, Boston MA) in the blocking buffer
was used as the secondary antibody. Blots were developed using
the LumiGLO reagents (Protein Research Products, Gaithers-
burg, MA) or the Western Lightning ECL Substrate (Perkin
Elmer Inc., Waltham, MA).
Activity-based proteomics for the identification of
activated metallohydrolases
Proteomes were adjusted to a concentration of 1 mg/ml in PBS.
A cocktail of alkyne probes targeting the active site of
metallohydrolases was a generous gift of Benjamin F Cravatt
(The Scripps Research Institute, La Jolla, CA). Labeling was
performed as previously described [10]. Briefly, probes were added
to a final concentration of 1 mM and incubated under UV light for
1 hr. Rhodamine azide was then bound to the probes using click
chemistry [11]. Samples were electrophoresed on a 10%
polyacrylamide gel and scanned using either a Hitachi FMBio
IIe flatbed scanner (MiraBio, Alameda, CA) or the KODAK In-
Vivo Multispectral System FX (Carestream Health, Rochester,
NY).
Identification of activity-based labeled proteins
Real-size gel scan prints were used as a template to extract the
desired bands and scanned afterwards to assure correct slicing of
the gel. Each gel plug was reduced with 10 mM dithiothreitol in
ammonium bicarbonate and alkylated with 55 mM iodoaceta-
mide. Samples were digested with 0.1 mg trypsin (Promega,
Madison, WI) in 100 ml of 10 mM ammonium bicarbonate and
incubated overnight at 37uC. Tryptic peptides were extracted
from gel plugs with 50% acetonitrile/49.9% H2O/0.1% trifluor-
oacetic acid followed by 100% acetonitrile and finally with 0.1%
trifluoroacetic acid.
Tryptic peptides were chromatographed on a 100 mm610 cm
C18 column (particle size: 5 mm) and eluted using a linear gradient
of 3 to 45% acetonitrile in H2O over 70 min at room temperature,
at a flow rate of 500 nl/min. The eluent was electro-sprayed into
the linear quadrupole ion trap (LTQ) mass spectrometer (Thermo-
Fisher Scientific, Waltham, MA). Sequest and X!Tandem
algorithms were used to search the database utilizing the
international protein index (IPI) mouse database.
Leukotriene B4 enzyme immunoassay
At 80% confluence, HT-29 cells were incubated with either
sulindac sulfide or DMSO for 24 hr. The secreted proteome was
obtained and concentrated by vacuum centrifugation. Proteomes
were adjusted to 5 mg/ml and LTB4 quantified with an enzymatic
immunoassay kit (Cayman Chemical, Ann Arbor, MI).
Results
The reduced metabolite of sulindac, sulindac sulfide,
selectively increases cell death of HT-29 cells
HT-29 cells were treated with sulindac, sulindac sulfide, and
sulindac sulfone at concentrations ranging from 10 to 1000 mM
(Figure 1). Starting at 250 mM, sulindac sulfide significantly
increased cell death, reaching 100% cell death at 500 mM. In
contrast, sulindac and sulindac sulfone failed to significantly
increase cell death, even when the drugs where added at mM
concentrations.
Sulindac sulfide reduces MMP7 at the mRNA, protein, and
activity levels
It was reported that two days of sulindac treatment is sufficient
to downregulate MMP7 in tumors of Apc
Min/+ mice [7]. In order to
determine which metabolite effectively diminished MMP7, HT-29
cells were treated with sulindac and its metabolites at 100 mM, a
concentration not toxic to the cells as demonstrated in figure 1, for
24 hr. The expression profile of MMP7 was compared to the
results previously obtained in mouse studies (Figure 2A). Only the
Table 1. Primers and probes.
Gene
1 sequence (59R39)T m (6C) GC (%)
MMP7 Forward GGATGGTAGCAGTCTAGGGATTAACT 61 46
Reverse GGAATGTCCCATACCCAAAGAA 61 45
Probe CCTGTATGCTGCAACTCATGAACTTGGC 68 50
RPL-19 Forward GCGGATTCTCATGGAACACA 58 50
Reverse GGTCAGCCAGGAGCTTCTTG 59 60
Probe CCACAAGCTGAAGGCAGACAAGGCC 70 60
Trypsin1 Forward CCCCCTTTGATGATGATGAC 60 50
Reverse GATGTCATTGTTCAGAGTCTTC 59 40
MMP25 Forward TCATGAGCTATGCCCTGATG 60 50
Reverse AGGGCCTCATAATGGAGTTG 59 50
1All genes are human.
doi:10.1371/journal.pone.0025725.t001
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reducing the expression of MMP7. A titration curve using different
concentrations of sulindac sulfide revealed that even at 50 mM,
MMP7 showed a small (14%), but statistically significant
downregulation of expression (p=0.044) (Figure 2B). At
100 mM, a decrease of 65% was observed (p=0.000001). The
difference between 100 mM and 200 mM was less dramatic (11%),
but was still significantly different between these two concentra-
tions (p=0.017).
Western blotting of MMP7, as well as the active site of MMP7,
was performed on cytosolic, membrane, and secreted fractions of
HT-29 proteomes after 24 hr of sulindac sulfide treatment at
100 mM (Figure 2C). In both cases, MMP7 was only detected in
the secreted fractions of the proteome. Sulindac sulfide treatment
showed a clear reduction of MMP7 in the secreted fraction at a
100 mM concentration. Western blot analysis targeting the active
site of MMP7 revealed a complete disappearance of detectable
active MMP7 after sulindac sulfide treatment.
In order to determine if other MMPs, other classes of proteases,
and the housekeeping gene, RPL-19, were affected by sulindac in
HT-29 cells, RT-PCR (whole cell extracts) and Western blot
(secreted, cytosolic, and fractions) analyses were performed.
mRNA for MMP25, trypsin1, and RPL-19 were not altered after
sulindac sulfide treatment (Figure 3A, B). Western blot analysis of
the membrane fraction of these cells confirmed RT-PCR results
for MMP25 (Figure 3C).
Figure 1. Percent cell death of HT-29 human colon cancer cells.
At 80% confluency, cells were treated with increasing concentrations of
sulindac (grey), sulindac sulfide (white), and sulindac sulfone (black).
doi:10.1371/journal.pone.0025725.g001
Figure 2. MMP7 expression in sulindac-treated cells. (A) Real time RT-PCR of RNA from HT-29 cells after 24 hours of treatment with DMSO,
sulindac (S), sulindac sulfide (Sd) and sulindac sulfone (Sn). The results were obtained using the DDCt method with hRPL-19 as the housekeeping
gene. CT values between 20.10 and 20.56 across all samples show constant levels of hRPL-19 expression. (B) The expression of hMMP7 after 24 hours
of sulindac treatment. The downregulation of hMMP7 was significant at all concentrations. The results were obtained using the DDCt method with
hRPL-19 as the housekeeping gene. CT values between 23.22 and 23.56 across all samples show constant levels of hRPL-19 expression. (C) Cytosolic,
membrane, and secreted proteome fractions extracted from DMSO- and sulindac sulfide-treated HT-29 cells were subjected to western blot analysis
using an antibody which does not differentiate between active and inactive MMP7 (top), and an antibody that only recognizes the active site
(bottom). The expected band for MMP7 appears at 28 kDa, however a band at 45 kDa is often reported, possibly a dimer. Cyto denotes cytosolic
fraction; Mem, membrane fraction, Secr, secreted fraction, and aMMP7, active MMP7.
doi:10.1371/journal.pone.0025725.g002
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metallohydrolases reveals a decrease in LTA4H activity
Proteomes extracted from HT-29 cells after 24 hr of treatment
with sulindac sulfide or DMSO were labeled with a probe cocktail
targeting the metallohydrolase superfamily and run on a 1D gel. A
strong band between 60 and 65 kDa was observed in HT-29 cells
treated with DMSO. Sulindac sulfide-treated cells showed a faint
band of similar molecular weight. The bands were excised and
analyzed by mass spectrometry. The samples were run by linear
quadrupole MS/MS (Figure 4) and the results matched with the
MEROPS database for metallohydrolases. There were two
peptides (LTYTAEVSVPK and LVVDLTDIDPDVAYSSV-
PYEK) detected in the ,70 kDa band that matched leukotriene
A4 hydrolase (LTA4H). The predicted molecular weight of
LTA4H is 69 kDa. LTA4H has previously been shown to be a
target for this metalloprotease probe cocktail (10).
In order to validate the reduction in LTA4H activity, an
enzymatic immunoassay was used to measure leukotriene B4
(LTB4) levels after sulindac treatment (Figure 5). Sulindac sulfide-
treated cells showed strongly reduced levels of LTB4 when
compared to DMSO-treated cells.
Discussion
The present study demonstrated that sulindac sulfide is capable
of reducing the RNA and protein levels of MMP7, which is
consistent with what was observed in mouse studies [7]. Through
activity-based protein profiling, it was demonstrated that sulindac
sulfide dramatically reduces the activity of LTA4H. This result was
validated by decreased levels of LTB4.
The involvement of metalloproteases in colon cancer has
previously been identified but the development of treatment
strategies targeting these enzymes has been unsuccessful [12]. One
problem is the low specificity of metalloprotease inhibitors that
have made it to clinical trials. MMP7, however, has consistently
been found to be relevant in colon cancer and its animal models
[9,13]. The present study indicated that sulindac sulfide is able to
reduce the expression of MMP7 in the human colon cancer cell
line HT-29 which was also observed, in vivo,i nApc
Min/+ mice [7].
In order to determine if other MMPs or other classes of proteases
were also altered, MMP25, a membrane-associated MMP that is
highly expressed in cancer cells [14], and trypsin1 were analysed
and shown to be unaffected by sulindac sulfide treatment.
Additionally, the housekeeping gene RPL-19 was also not affected
by this NSAID. Nobiletin, another agent with anticancer
properties, has also been shown to downregulate MMP7 [15] in
HT-29 cells. Several mechanisms have been proposed by which
MMP7 promotes tumor growth. Several of those studies link
MMP7 with a disrupted Fas-mediated apoptotic response
[16,17,18], and inflammation-related facilitation of tumor growth
has been proposed to be caused by MMP7 cleavage of Fas ligand
[19].
Figure 3. MMP7, MMP25, Trypsin1 and RPL-19 expression in sulindac sulfide-treated cells. (A) PCR product of RT-PCR of RNA from HT-29
cells after 24 hours of treatment with DMSO or sulindac sulfide. Lane 1, 50 bp DNA ladder; lane 2, MMP25 after sulindac sulfide treatment; lane 3,
MMP25 after DMSO treatment; lane 4, Trypsin1 after sulindac sulfide treatment; lane 5, Trypsin1 after DMSO treatment; lane 6, MMP7 after sulindac
sulfide treatment; lane 7, MMP7 after DMSO treatment; lane 8 RPL-19 after sulindac sulfide treatment; lane 9, RPL-19 after DMSO treatment. Results
demonstrate that only MMP7 expression is affected by sulindac sulfide treatment. (B) Quantitative RT-PCR of MMP25, Trypsin1, and MMP7 after DMSO
or sulindac sulfide treatment. The results were obtained using the DDCt method with hRPL-19 as the housekeeping gene. Results indicate
quantitative differences in MMP7 expression after sulindac sulfide treatment relative to DMSO treatment. (C) Western blot of secreted fraction of HT-
29 cells demonstrating that the protein levels of MMP25 in the membrane fraction are similar between sulindac sulfide and DMSO treated cells.
doi:10.1371/journal.pone.0025725.g003
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family of metallohydrolases. These proteases have been implicated
in several cancers including aminopeptidase N in colon cancer
[20], cystinyl aminopeptidase in renal cancer [21], and LTA4H in
lung and colon adenocarcinomas [22]. This is the first study
linking sulindac to regulating LTA4H. The downregulation of
activity of LTA4H, and decrease in tumor burden, after sulindac
treatment supports studies in which it has been shown to be
upregulated in colon cancer. Furthermore, [6]-gingerol, a natural
component with antitumorigenic properties, has been found to
suppress cancer growth by LTA4H inhibition [23]. The decrease
in LTA4H activity was validated by the observation that lower
LTB4 levels were found after sulindac treatment. LTB4 is a well
known eicosanoid with chemotactic properties and has been
shown to stimulate the proliferation, in vitro, of HT-29 colon
cancer cells [24].
There has been no other report of the involvement of sulindac,
or any other NSAID, on MMP7 or LTA4H expression. However,
in preliminary studies, we have shown that sulindac is not the only
NSAID capable of downregulating MMP7, i.e., aspirin (data not
shown), which suggests that MMP7 is downregulated by a shared
NSAID mechanism [7,25] and not a unique property of sulindac.
In summary, the present study identified two candidates,
previously reported to be highly relevant in tumor development,
that are altered after sulindac treatment. New treatment modalities
selectively targeting MMP7 and LTA4H, individually or in
combination, offer new therapeutic approaches that take advan-
tage of the benefits of sulindac treatment, but potentially without
the adverse side effects of this drug.
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